Mereo Biopharma Group PLC To Discuss ACTIVATE Phase 1b/2 Open Label Study of etigilimab Anti-TIGIT Antibody in combination with Nivolumab in Solid Tumors Call Transcript
Good day, and thank you for standing by. Welcome to the etigilimab ACTIVATE trial update call. (Operator Instructions) Please be advised, today's conference may be recorded. (Operator Instructions) I'd now like to hand the conference over to Denise Scots-Knight, Chief Executive Officer. Please go ahead.
Thank you, operator. Thank you to everybody for joining us today. We're excited to share our update on the Phase 1b/2 ACTIVATE study with our anti-TIGIT antibody, etigilimab, in combination with nivolumab.
The next slide, slide 2, is the disclaimer. So I will move on from that to the agenda. So first of all, Dr. John Lewicki, our CSO, is going to provide a reminder on etigilimab and the historical data. Dr. Suba Krishnan, our SVP Clinical Development, who heads up the program, will then present an update on the clinical data. This will be followed by Dr. Ann Kapoun, our SVP Translational R&D, who will present our tumor selection rationale and our biomarker results to date on the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
